Natera, Inc. $NTRA Stock Position Lessened by ARK Investment Management LLC

ARK Investment Management LLC reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 4.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 892,593 shares of the medical research company’s stock after selling 43,799 shares during the quarter. ARK Investment Management LLC’s holdings in Natera were worth $143,681,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares during the period. Rakuten Investment Management Inc. acquired a new position in shares of Natera during the third quarter valued at approximately $34,096,000. New York State Common Retirement Fund raised its holdings in Natera by 63.2% during the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after purchasing an additional 57,400 shares in the last quarter. SWS Partners lifted its position in Natera by 11.8% in the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares during the period. Finally, Vontobel Holding Ltd. boosted its stake in Natera by 192.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity

In related news, insider Solomon Moshkevich sold 23,205 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. This represents a 13.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 85,299 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the sale, the chief executive officer owned 127,881 shares of the company’s stock, valued at $29,504,704.32. The trade was a 40.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 367,669 shares of company stock valued at $85,584,453 in the last ninety days. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $203.03 on Thursday. The firm has a 50 day simple moving average of $224.59 and a 200 day simple moving average of $204.76. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The company has a market cap of $28.78 billion, a PE ratio of -132.70 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the previous year, the business earned ($0.41) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NTRA shares. Citigroup initiated coverage on Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Stephens upped their price target on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Piper Sandler lifted their price objective on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, UBS Group boosted their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $253.47.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.